Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $91
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.
Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.
